How PGT-M Prevents Common Genetic Diseases
Preimplantation Genetic Test-Monogenic (PGT-M) is a new and innovative technology used in conjunction with IVF. PGT-M prevents a parent who is a known carrier of a single gene disorder from passing that disease on to a baby conceived via IVF.
PGT-M Embryo Screening
PGT-M screens embryos for the presence of common genetic diseases in conjunction with IVF.
- Hemophilia
- Cystic Fibrosis
- Sickle Cell Anemia
- Tay Saches Disease
- Spinal Muscular Atrophy
- Duchennes Muscular Dystophy
- Thalassemia
After a woman’s eggs have been surgically retrieved and fertilized in vitro, developing embryos will be tested upon reaching the blastocyst stage (5 to 6 days after fertilization occurs). A few cells are gently removed from each embryo using microsurgery technology. Our expert embryologists then analyze the cells using a probe that is specifically designed to test for a specific gene disorder. PGT-M diagnoses the presence of a genetic defect in an embryo.
Only Healthy Embryos Are Transferred
Embryos testing positive for a genetic disease are not transferred to the woman’s uterus. Only healthy embryos are used for a fresh transfer or cryopreserved for future Frozen Embryo Transfer (FET) procedures.
PGT-M is conducted in conjunction with Cutting-Edge IVF Protocols.
Candidates for PGT-M
- Women over 35 undergoing IVF using their own eggs
- Couples having a history of multiple failed IVF attempts
- Patients having a family history of genetic disease
- Couples where one or both partners are known carriers of genetic disease
- Couple who have a child born with a genetic disease
- Couples who have a history of recurrent miscarriage
PGT-M Technology Expertise
Dr. John Zhang’s PGT-M technology expertise in conjunction with IVF offers the highest pregnancy success rates and best overall patient satisfaction. To schedule your initial consultation with Dr. John Zhang call 212.969.7422.
